The patient received 4 cycles combination immunotherapy and platinum-based chemotherapy, specifically: tislelizumab 200mg d1 + paclitaxel for injection (albumin bound) 400mg d1 + Cisplatin 500mg d1 every three weeks, A follow-up chest CT with enhancement showed that the tumor volume and lymph nodes had significantly decreased compared to before with (RECIST) version 1.1 evaluation showing PR (Figures 6C, D). The gene discussed is ALB; the disease is neoplasm.